PortalPublikationenMultibiomarker panels in liquid biopsy for early detection o...

Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review

Standard

Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review. / Reese, Kim-Lea; Pantel, Klaus; Smit, Daniel J.

in: J EXP CLIN CANC RES, Jahrgang 43, Nr. 1, 250, 02.09.2024.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Reese, K-L, Pantel, K & Smit, DJ 2024, 'Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review', J EXP CLIN CANC RES, Jg. 43, Nr. 1, 250. https://doi.org/10.1186/s13046-024-03166-w

APA

Reese, K-L., Pantel, K., & Smit, D. J. (2024). Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review. J EXP CLIN CANC RES, 43(1), [250]. https://doi.org/10.1186/s13046-024-03166-w

Vancouver

Reese K-L, Pantel K, Smit DJ. Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review. J EXP CLIN CANC RES. 2024 Sep 2;43(1). 250. https://doi.org/10.1186/s13046-024-03166-w

Bibtex

@article{b4710c562e35407d81e1ce28f81abd53,
title = "Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of early-stage PDAC that can be used for targeted screening approaches is available. Liquid biopsy allows the minimally invasive collection of body fluids (typically peripheral blood) and the subsequent analysis of circulating tumor cells or tumor-associated molecules such as nucleic acids, proteins, or metabolites that may be useful for the early diagnosis of PDAC. Single biomarkers may lack sensitivity and/or specificity to reliably detect PDAC, while combinations of these circulating biomarkers in multimarker panels may improve the sensitivity and specificity of blood test-based diagnosis. In this narrative review, we present an overview of different liquid biopsy biomarkers for the early diagnosis of PDAC and discuss the validity of multimarker panels.",
keywords = "Humans, Liquid Biopsy/methods, Pancreatic Neoplasms/diagnosis, Early Detection of Cancer/methods, Biomarkers, Tumor/blood, Carcinoma, Pancreatic Ductal/diagnosis",
author = "Kim-Lea Reese and Klaus Pantel and Smit, {Daniel J}",
note = "{\textcopyright} 2024. The Author(s).",
year = "2024",
month = sep,
day = "2",
doi = "10.1186/s13046-024-03166-w",
language = "English",
volume = "43",
journal = "J EXP CLIN CANC RES",
issn = "1756-9966",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review

AU - Reese, Kim-Lea

AU - Pantel, Klaus

AU - Smit, Daniel J

N1 - © 2024. The Author(s).

PY - 2024/9/2

Y1 - 2024/9/2

N2 - Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of early-stage PDAC that can be used for targeted screening approaches is available. Liquid biopsy allows the minimally invasive collection of body fluids (typically peripheral blood) and the subsequent analysis of circulating tumor cells or tumor-associated molecules such as nucleic acids, proteins, or metabolites that may be useful for the early diagnosis of PDAC. Single biomarkers may lack sensitivity and/or specificity to reliably detect PDAC, while combinations of these circulating biomarkers in multimarker panels may improve the sensitivity and specificity of blood test-based diagnosis. In this narrative review, we present an overview of different liquid biopsy biomarkers for the early diagnosis of PDAC and discuss the validity of multimarker panels.

AB - Pancreatic ductal adenocarcinoma (PDAC) is frequently detected in late stages, which leads to limited therapeutic options and a dismal overall survival rate. To date, no robust method for the detection of early-stage PDAC that can be used for targeted screening approaches is available. Liquid biopsy allows the minimally invasive collection of body fluids (typically peripheral blood) and the subsequent analysis of circulating tumor cells or tumor-associated molecules such as nucleic acids, proteins, or metabolites that may be useful for the early diagnosis of PDAC. Single biomarkers may lack sensitivity and/or specificity to reliably detect PDAC, while combinations of these circulating biomarkers in multimarker panels may improve the sensitivity and specificity of blood test-based diagnosis. In this narrative review, we present an overview of different liquid biopsy biomarkers for the early diagnosis of PDAC and discuss the validity of multimarker panels.

KW - Humans

KW - Liquid Biopsy/methods

KW - Pancreatic Neoplasms/diagnosis

KW - Early Detection of Cancer/methods

KW - Biomarkers, Tumor/blood

KW - Carcinoma, Pancreatic Ductal/diagnosis

U2 - 10.1186/s13046-024-03166-w

DO - 10.1186/s13046-024-03166-w

M3 - SCORING: Review article

C2 - 39218911

VL - 43

JO - J EXP CLIN CANC RES

JF - J EXP CLIN CANC RES

SN - 1756-9966

IS - 1

M1 - 250

ER -